This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Alexion Pharmaceuticals Inc (ALXN)

NASDAQ: Health Care

Company Income Statement
Dec 2015 Dec 2014 Dec 2013 Dec 2012
Sales 2.60B 2.23B 1.55B 1.13B
Cost of Sales 176.27M 111.40M 146.04M 102.74M
Gross Operating Profit 2.43B 2.12B 1.41B 1.03B
Selling, General, and Administrative Expenses 862.60M 630.21M 489.72M 384.68M
Research & Development 709.47M 513.78M 317.09M 222.73M
Operating Income before D & A (EBITDA) 855.71M 978.34M 598.49M 423.96M
Depreciation & Amortization 173.40M 62.46M 31.93M 23.89M
Interest Income 8.52M 8.37M 3.35M 1.84M
Other Income - Net -38.51M -1.99M -975.00K 52.17M
Special Income / Charges -64.26M -11.51M -33.52M -26.30M
Total Income Before Interest Expenses (EBIT) 545.89M 875.09M 530.38M 404.97M
Interest Expense 47.74M 2.98M 4.11M 7.40M
Pre-Tax Income 498.14M 872.11M 526.27M 397.57M
Income Taxes 353.76M 215.19M 273.37M 142.74M
Minority Interest 0.00 0.00 0.00 0.00
Net Income From Continuing Operations 144.38M 656.91M 252.90M 254.82M
Net Income From Discontinued Operations 0.00 0.00 0.00 0.00
Net Income From Total Operations 144.38M 656.91M 252.90M 254.82M
Extraordinary Income/Losses 0.00 0.00 0.00 0.00
Income From Cum. Effect of Acct. Change 0.00 0.00 0.00 0.00
Income From Tax Loss Carryforward 0.00 0.00 0.00 0.00
Other Gains / Losses 0.00 0.00 0.00 0.00
Total Net Income 144.38M 656.91M 252.90M 254.82M
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
250.81M 704.09M 291.44M 303.93M
Preferred Dividends
Net Income Available To Common 144.38M 656.91M 252.90M 254.82M
Basic EPS from Continuing Ops. 0.68 3.32 1.29 1.34
Basic EPS from Discontinued Ops. 0.00 0.00 0.00 0.00
Basic EPS from Total Operations 0.68 3.32 1.29 1.34
Basic EPS from Extraordinary Inc. 0.00 0.00 0.00 0.00
Basic EPS from Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
Basic EPS from Tax Loss Carryf'd. 0.00 0.00 0.00 0.00
Basic EPS from Other Gains (Losses) 0.00 0.00 0.00 0.00
Basic EPS, Total 0.68 3.32 1.29 1.34
Basic Normalized Net Income/Share 1.18 3.55 1.49 1.60
EPS fr Continuing Ops. 0.67 3.26 1.27 1.28
EPS fr Discontinued Ops 0.00 0.00 0.00 0.00
EPS fr Total Ops. 0.67 3.26 1.27 1.28
EPS fr Extraord. Inc. 0.00 0.00 0.00 0.00
EPS fr Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
EPS fr Tax Loss Carfd. 0.00 0.00 0.00 0.00
EPS fr Other Gains (L) 0.00 0.00 0.00 0.00
EPS, Total 0.67 3.26 1.27 1.28
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
1.16 3.49 1.46 1.53
Dividends Paid per Share 0.00 0.00 0.00 0.00
ALXN News

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

ALXN Alexion Pharmaceuticals Inc

Chart of ALXN

Analysts Ratings for ALXN

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 13 13 14 12
Moderate Buy 1 1 1 1
Hold 5 4 3 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET ALXN ANALYST REPORT

ALXN Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs